Urothelial Superior Vena Cava Syndrome with Limited Response to Radiation Therapy

TL;DR

This paper discusses a rare case of SVC syndrome caused by urothelial cancer and highlights the limited effectiveness of radiation therapy in advanced cases.

Contribution

The paper presents a rare case of urothelial carcinoma causing SVC syndrome and emphasizes the need for alternative treatment approaches in advanced disease.

Findings

Urgent radiation therapy was insufficient to manage advanced metastatic urothelial cancer with SVC syndrome.

Stenting and chemotherapy may be more effective initial treatments for advanced SVC syndrome cases.

Only three cases of SVC syndrome due to urothelial carcinoma have been reported in the literature.

Abstract

Radiation therapy (RT) is the standard of care for cases of superior vena cava (SVC) syndrome secondary to metastatic adenopathy. Histologies vary in radiosensitivity and response time, making alternative therapies such as chemotherapy and/or intravenous stenting preferable alternative options for certain diagnoses. Metastatic urothelial carcinoma is a particularly rare cause of SVC syndrome with only 3 cases reported in the literature. Consequently, optimal management remains challenging, particularly in cases of high tumor burden. Here we present a case of highly advanced metastatic urothelial cancer with SVC syndrome and tracheal compression. The patient started urgent RT but expired midway through her treatment course due to systemic progression of disease, requiring SVC and tracheal stenting. The authors review the literature including discussion of the few other known cases of SVC syndrome due to urothelial carcinoma and a review of this histology's response to RT. This experience suggests, that in cases of SVC syndrome with widespread advanced disease, stenting and chemotherapy with or without RT may be the most important initial treatment plan, depending on goals of care.

Figures